Can a targeted antibody calm severe eczema?
NCT ID NCT07746817
First seen Aug 05, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This first-in-human trial evaluates BYN-001, an antibody designed to block IL-25, a protein linked to atopic dermatitis (eczema). The study first tests the drug in healthy volunteers to assess safety and how it moves through the body, then in people with moderate to severe eczema. The goal is to see if BYN-001 is safe, tolerable, and potentially effective for treating this chronic skin condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BYN-001, a humanized monoclonal antibody that blocks interleukin-25 (IL-25), given by subcutaneous injection
- What this could lead to
- If successful, this could lead to a new treatment option for moderate to severe atopic dermatitis, potentially reducing symptoms like itching and skin inflammation.
- What could go wrong
- This is an early-phase trial, so safety and effectiveness are not yet established. The drug may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out